ArticleMedical science monitor : international medical journal of experimental and clinical research2022

Editorial: Treatment with Dual Incretin Receptor Agonists to Maintain Normal Glucose Levels May Also Maintain Normal Weight and Control Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD).

Ana Luisa Ordóñez-Vázquez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.